Best MOTS-c Suppliers in 2026: 51 Sellers, Priced per mg

MOTS-c is having a moment: a July 2026 FDA advisory committee vote just recommended it for compounding, over the FDA's own staff recommendation against it. Fifty-one vendors now carry it, priced anywhere from $1.00 to $13.90 per mg. Here's who we'd actually buy from, and what the human evidence for MOTS-c actually says right now, which is less than the hype suggests.

Where the market sits right now

We track 51 sellers carrying MOTS-c, and 48 of them ship to US addresses. From our latest price run:

Full sortable pricing lives on our MOTS-c vendor page, normalized per milligram on the price index.

The vendors we would actually use

Same rubric as everywhere else on this site: independent lab testing weighted heaviest, then price per mg, US shipping, reputation, catalog depth, payment options. Full method in how we score vendors.

Peptidology: best paper trail, but check stock first

$3.25 per mg, Finnrick tested, the highest overall scorecard on our board. The catch: at the time of writing, only a 61mg bulk size ($43.99) was in stock — the smaller 10mg and 40mg sizes were sold out. Worth a check before you count on it. Full scorecard.

Orbitrex Peptides: our pick if you want a working coupon on top of a fair price

$3.999 per mg, Finnrick tested, shipping from Flower Mound, Texas, 10mg in stock at $39.99. Orbitrex is also the one vendor on our entire MOTS-c list where we've verified an active discount code — see our coupon codes page for the current offer, which stacks on top of an already-competitive price here.

Verified Peptides: solid mid-market pick

$3.85 per mg, Finnrick tested, 20mg in stock at $77.00. Consistent with how this vendor scores across most peptides we track: reliable testing, fair pricing, credit card only. Full scorecard.

Atomik Labz: cheapest of the well-tested options

$2.475 per mg, Finnrick tested — the best combination of low price and top-tier lab verification on this list. Both 10mg ($45) and 40mg ($99) are in stock, which also makes it worth checking the vial-arbitrage math below before you pick a size. Full scorecard.

NuLife Peptides: the wide-payment option

$4.50 per mg, Finnrick tested, 10mg at $70 and 20mg at $90 both in stock, and takes ACH, Apple Pay, credit card, or Zelle. Full scorecard.

Also worth noting: Peptide Technologies runs $5.995 per mg out of Sheridan, Wyoming (Finnrick tested, 10mg at $59.95). VPeptide Canada has the cheapest top-tier-lab price on the whole list at $1.911 per mg, but ships within Canada only.

Bigger vials save real money here — check the spread

MOTS-c has some of the widest vial-arbitrage gaps we track. Atomik Labz prices a 10mg vial at $45.00 ($4.50/mg) against a 40mg vial at $99.00 ($2.48/mg) — a 45 percent premium for buying small. Enhanced Biolabs is worse: 10mg at $74.99 versus 40mg at $119.99, a 60 percent premium, the biggest gap on this list. Licensed Peptides runs a 55 percent premium on its smallest size. If a vendor sells more than one vial size, it is almost always worth pricing both before you buy.

What the FDA vote actually means (and doesn't)

MOTS-c had an unusual path through the FDA's Pharmacy Compounding Advisory Committee (PCAC). Ahead of the July 23-24, 2026 meeting, FDA staff's own briefing document proposed that MOTS-c free base and MOTS-c acetate NOT be added to the 503A Bulks List. The committee disagreed: on July 23, it voted 7-5 with 2 abstentions to recommend MOTS-c for inclusion anyway, overriding the agency's own staff recommendation. MOTS-c was one of six peptides the committee waved through that meeting (alongside BPC-157, KPV, TB-500, Semax, and Epitalon); only Emideltide/DSIP was rejected outright.

That is a real regulatory signal, but per the National Community Pharmacists Association's own reporting, PCAC votes are recommendations only — not binding. HHS Secretary Robert F. Kennedy Jr. still has to formally approve the list, and pharmacies cannot legally compound MOTS-c until final rulemaking is in place. Nothing about the vote changes what has or hasn't been proven about MOTS-c in humans, which is the part most coverage skips.

The evidence: strong mechanism, thin human data

MOTS-c was discovered by Lee et al. in a 2015 Cell Metabolism paper (PMID 25738459) — a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene, translated in the cytoplasm rather than the mitochondrion itself, that the authors showed regulates insulin sensitivity and reduces obesity in animal models. That paper is animal and mechanism work, not a human clinical trial, and it's the foundation almost everything else in the MOTS-c story builds on.

The best human evidence to date is observational and exercise-based, not a drug trial. Reynolds et al., published in Nature Communications in 2021 (PMID 33473109), studied 10 sedentary healthy young men on a graded cycling protocol and measured their own endogenous MOTS-c response to exercise: skeletal muscle MOTS-c rose 11.9-fold immediately after exercise, and circulating plasma MOTS-c rose roughly 1.5- to 1.6-fold during and immediately after exercise, both returning toward baseline after four hours of rest. That tells us MOTS-c is a real, exercise-responsive signal in the human body — it does not tell us anything about what happens when you inject supplemental MOTS-c into a person.

For that question — does administering MOTS-c to humans actually do anything — there is currently one ongoing trial and no completed one. NCT07505745 ("MOTS-MET"), sponsored by Hudson Biotech, is a randomized, double-blind, placebo-controlled Phase 2a trial in 120 adults with prediabetes or overweight/obesity. It started February 2, 2026, is still recruiting, and its estimated primary completion date is February 2027. No results have been posted. Until that reads out, there is no completed human efficacy trial of injected MOTS-c for any condition — everything else circulating about MOTS-c's effects in people is animal data, mechanism, or the exercise-response study above, not a treatment trial.

That gap doesn't mean MOTS-c is fake or worthless as a research compound — the mitochondrial biology is genuinely interesting and well-published. It means anyone telling you MOTS-c is "proven" to reverse insulin resistance or aging in humans is ahead of the actual data. Keep that in mind against the price you're paying, and treat this strictly as a research compound, not a treatment, until NCT07505745 reads out.

Sources